- Home
- DHAI vs BCDA Comparison
DHAI vs BCDA Comparison
Compare DHAI & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHAI
- BCDA
- Stock Information
- Founded
- DHAI 2007
- BCDA N/A
- Country
- DHAI United States
- BCDA United States
- Employees
- DHAI N/A
- BCDA N/A
- Industry
- DHAI
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- DHAI
- BCDA Health Care
- Exchange
- DHAI NYSE
- BCDA Nasdaq
- Market Cap
- DHAI 10.5M
- BCDA 11.0M
- IPO Year
- DHAI N/A
- BCDA N/A
- Fundamental
- Price
- DHAI $0.25
- BCDA $2.00
- Analyst Decision
- DHAI
- BCDA Strong Buy
- Analyst Count
- DHAI 0
- BCDA 1
- Target Price
- DHAI N/A
- BCDA $25.00
- AVG Volume (30 Days)
- DHAI 6.2M
- BCDA 54.0K
- Earning Date
- DHAI 08-18-2025
- BCDA 08-12-2025
- Dividend Yield
- DHAI N/A
- BCDA N/A
- EPS Growth
- DHAI N/A
- BCDA N/A
- EPS
- DHAI N/A
- BCDA N/A
- Revenue
- DHAI $69,573,000.00
- BCDA $3,000.00
- Revenue This Year
- DHAI N/A
- BCDA N/A
- Revenue Next Year
- DHAI N/A
- BCDA N/A
- P/E Ratio
- DHAI N/A
- BCDA N/A
- Revenue Growth
- DHAI 5.40
- BCDA N/A
- 52 Week Low
- DHAI $0.12
- BCDA $1.63
- 52 Week High
- DHAI $3.67
- BCDA $4.66
- Technical
- Relative Strength Index (RSI)
- DHAI 56.22
- BCDA 42.37
- Support Level
- DHAI $0.24
- BCDA $1.98
- Resistance Level
- DHAI $0.30
- BCDA $2.45
- Average True Range (ATR)
- DHAI 0.04
- BCDA 0.17
- MACD
- DHAI 0.00
- BCDA -0.01
- Stochastic Oscillator
- DHAI 46.14
- BCDA 10.00
About DHAI DIH HOLDINGS US INC
DIH Holding US Inc is a provider of robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Its products Armeo Power, Armeo Spring, Armeo Spring Pro, etc.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).